Bafna (BAFNAPH) | Financial Analysis & Statements
Bafna Pharmaceuticals Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
346.2M
Gross Profit
122.1M
35.25%
Operating Income
37.0M
10.68%
Net Income
33.9M
9.79%
EPS (Diluted)
₹1.43
Balance Sheet Metrics
Total Assets
1.5B
Total Liabilities
682.7M
Shareholders Equity
848.1M
Debt to Equity
0.81
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Bafna Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.5B | 1.5B | 1.2B | 851.4M | 712.2M |
| Cost of Goods Sold | 1.0B | 1.1B | 765.9M | 512.8M | 454.6M |
| Gross Profit | 428.0M | 455.6M | 387.6M | 338.6M | 257.6M |
| Gross Margin % | 29.3% | 29.9% | 33.6% | 39.8% | 36.2% |
| Operating Expenses | |||||
| Research & Development | 14.5M | 2.7M | 7.2M | 14.7M | - |
| Selling, General & Administrative | 30.8M | 85.3M | 20.4M | 25.8M | 7.8M |
| Other Operating Expenses | 56.7M | 54.2M | 38.6M | 30.2M | 18.6M |
| Total Operating Expenses | 102.0M | 142.1M | 66.3M | 70.6M | 26.4M |
| Operating Income | 69.6M | 74.0M | 120.7M | 66.1M | 61.4M |
| Operating Margin % | 4.8% | 4.9% | 10.5% | 7.8% | 8.6% |
| Non-Operating Items | |||||
| Interest Income | 1.4M | 1.3M | 445.0K | 336.0K | 395.0K |
| Interest Expense | 25.6M | 19.4M | 18.0M | 5.2M | 886.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 41.5M | 73.5M | 116.2M | 52.2M | 58.3M |
| Income Tax | 0 | 0 | 2.8M | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 2.4% | 0.0% | 0.0% |
| Net Income | 41.5M | 73.5M | 113.4M | 52.2M | 58.3M |
| Net Margin % | 2.8% | 4.8% | 9.8% | 6.1% | 8.2% |
| Key Metrics | |||||
| EBITDA | 136.1M | 142.9M | 187.0M | 133.6M | 103.9M |
| EPS (Basic) | ₹1.76 | ₹3.11 | ₹4.79 | ₹2.21 | ₹2.46 |
| EPS (Diluted) | ₹1.76 | ₹3.11 | ₹4.79 | ₹2.21 | ₹2.46 |
| Basic Shares Outstanding | 23656000 | 23656000 | 23656000 | 23656000 | 23685772 |
| Diluted Shares Outstanding | 23656000 | 23656000 | 23656000 | 23656000 | 23685772 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Bafna Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 34.3M | 14.0M | 78.1M | 194.0K | 7.5M |
| Short-term Investments | - | 7.0M | - | - | - |
| Accounts Receivable | 401.7M | 453.9M | 411.5M | 147.8M | 95.6M |
| Inventory | 280.9M | 296.4M | 222.2M | 202.8M | 154.4M |
| Other Current Assets | 127.1M | 166.1M | 156.0M | 161.7M | -1.0K |
| Total Current Assets | 847.3M | 944.7M | 873.1M | 508.8M | 496.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 192.2M | 148.5M | 141.3M | 131.1M | 393.1M |
| Goodwill | 0 | 17.7M | 15.0M | 0 | 0 |
| Intangible Assets | - | 17.7M | 15.0M | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | -2.0K | -3.0K | -2.0K | -2.0K |
| Total Non-Current Assets | 683.5M | 532.1M | 422.7M | 392.6M | 368.0M |
| Total Assets | 1.5B | 1.5B | 1.3B | 901.4M | 864.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 309.5M | 354.2M | 284.6M | 124.0M | 106.9M |
| Short-term Debt | 141.7M | 136.4M | 144.9M | 57.4M | 105.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 26.0M | 18.3M | 21.2M | 21.5M | 21.5M |
| Total Current Liabilities | 518.5M | 540.8M | 464.8M | 220.1M | 243.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 140.3M | 107.5M | 84.3M | 53.2M | 25.0M |
| Deferred Tax Liabilities | - | - | - | 0 | 0 |
| Other Non-Current Liabilities | - | 3.0K | - | 10.7M | 1.0K |
| Total Non-Current Liabilities | 164.2M | 127.6M | 96.5M | 61.7M | 53.9M |
| Total Liabilities | 682.7M | 668.4M | 561.3M | 281.8M | 296.9M |
| Equity | |||||
| Common Stock | 236.6M | 236.6M | 236.6M | 236.6M | 236.6M |
| Retained Earnings | -431.3M | -471.0M | -544.8M | -659.7M | -711.7M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 848.1M | 808.4M | 734.5M | 619.6M | 567.7M |
| Key Metrics | |||||
| Total Debt | 282.0M | 243.9M | 229.2M | 110.6M | 130.0M |
| Working Capital | 328.8M | 403.9M | 408.4M | 288.7M | 253.6M |
Balance Sheet Composition
Bafna Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 41.5M | 73.5M | 116.2M | 51.9M | 58.3M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | 120.1M | -126.8M | -297.0M | -145.7M | -214.0M |
| Operating Cash Flow | 207.7M | -32.7M | -164.1M | -93.7M | -162.4M |
| Investing Activities | |||||
| Capital Expenditures | -218.0M | -154.1M | -65.2M | -75.4M | -60.9M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -5.0K | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -213.0M | -149.1M | -60.2M | -65.6M | -53.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | - | - | - | -88.2M | 98.7M |
| Free Cash Flow | 2.8M | -63.6M | -32.7M | 21.9M | -197.0M |
| Net Change in Cash | -5.4M | -181.8M | -224.3M | -247.5M | -117.5M |
Cash Flow Trend
Bafna Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
32.31
Price to Book
3.43
Price to Sales
2.18
PEG Ratio
0.34
Profitability Ratios
Profit Margin
6.55%
Operating Margin
3.87%
Return on Equity
4.90%
Return on Assets
2.71%
Financial Health
Current Ratio
1.67
Debt to Equity
35.52
Beta
-0.02
Per Share Data
EPS (TTM)
₹4.09
Book Value per Share
₹38.54
Revenue per Share
₹62.38
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BAFNAPH | 3.3B | 32.31 | 3.43 | 4.90% | 6.55% | 35.52 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





